Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer.

37 Furthermore, whereas out-of-pocket costs for IV medicines have remained fairly constant, there is an increasing trend in out-of-pocket costs for oral targeted medicines. 38 , 39 Higher prescription drug pricing has the potential to affect initiation and adherence of these medicines with data showing that up to 41% of patients with copay between $100 and $500 and 67% of patients with co-pay more than $2000 did not

also in 63,971 other papers